Access Policy for ALS
The recently completed phase 3 REFALS clinical trial did not reach its most important endpoints, indicating no significant benefit of oral levosimendan in the treatment of ALS. Accordingly, the development of oral levosimendan for ALS has been terminated, and we have made the difficult decision that it would not be appropriate to provide access to oral levosimendan for the treatment of ALS.
We would like to express our warmest thanks to all the people living with ALS, their care partners and the investigators who have participated in our clinical trials. Orion together with the international scientific community continues to find ways to fight ALS.
For additional information about this policy, please contact email@example.com. We will reply as quickly as possible but aim to take no longer than one business week.